HEMANGEOL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Hemangeol, and what generic alternatives are available?
Hemangeol is a drug marketed by Pierre Fabre and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has forty-seven patent family members in thirty-one countries.
The generic ingredient in HEMANGEOL is propranolol hydrochloride. There are twenty-two drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the propranolol hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Hemangeol
A generic version of HEMANGEOL was approved as propranolol hydrochloride by INNOGENIX on October 22nd, 1985.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for HEMANGEOL?
- What are the global sales for HEMANGEOL?
- What is Average Wholesale Price for HEMANGEOL?
Summary for HEMANGEOL
International Patents: | 47 |
US Patents: | 2 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 156 |
Clinical Trials: | 4 |
Patent Applications: | 4,079 |
Drug Prices: | Drug price information for HEMANGEOL |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for HEMANGEOL |
What excipients (inactive ingredients) are in HEMANGEOL? | HEMANGEOL excipients list |
DailyMed Link: | HEMANGEOL at DailyMed |
Recent Clinical Trials for HEMANGEOL
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Christiana Care Health Services | Phase 1 |
Columbia University | Phase 2 |
United States Department of Defense | Early Phase 1 |
Pharmacology for HEMANGEOL
Drug Class | beta-Adrenergic Blocker |
Mechanism of Action | Adrenergic beta-Antagonists |
Paragraph IV (Patent) Challenges for HEMANGEOL
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
HEMANGEOL | Oral Solution | propranolol hydrochloride | 4.28 mg/mL | 205410 | 1 | 2022-07-21 |
US Patents and Regulatory Information for HEMANGEOL
HEMANGEOL is protected by two US patents.
Patents protecting HEMANGEOL
Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD TO TREAT HEMANGIOMA.
Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD TO TREAT INFANTILE HEMANGIOMA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pierre Fabre | HEMANGEOL | propranolol hydrochloride | SOLUTION;ORAL | 205410-001 | Mar 14, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Pierre Fabre | HEMANGEOL | propranolol hydrochloride | SOLUTION;ORAL | 205410-001 | Mar 14, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for HEMANGEOL
See the table below for patents covering HEMANGEOL around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Colombia | 6270209 | UN BETA BLOQUEANTE PARA EL TRATAMIENTO DE LOS HEMANGIOMAS | ⤷ Sign Up |
Denmark | 2233135 | ⤷ Sign Up | |
European Patent Office | 2050441 | Utilisation de bêtabloquants pour la fabrication d'un médicament pour le traitement d'hémangiomes (Use of beta blocker for the manufacture of a medicament for the treatment of hemangiomas) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |